| 产品名称: | 5A1 |
|---|---|
| 商品货号: | TS212820 |
| Organism: | Rattus norvegicus (B cell); Rattus norvegicus (myeloma), rat (B cell); rat (myeloma) |
| Tissue: | spleen |
| Cell Type: | hybridoma:lymphoblast B lymphocyte; somatic cell hybri |
| Product Format: | frozen |
| Morphology: | lymphoblast |
| Culture Properties: | suspension |
| Biosafety Level: | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications: | ELISA detection colony stimulating factor 1 (macrophage) |
| Storage Conditions: | liquid nitrogen vapor phase |
| Derivation: | Animals were immunized with purified mouse colony stimulating factor-1 (CSF-1). Spleen cells were fused with Y3-Ag.1.2.3 myeloma cells. The D24 (ATCC CRL-2701) antibody binds to mouse CSF-1 but does not neutralize its biological activity while the 5A1 (TS212820) antibody binds to and neutralizes the biological function of CSF-1 PubMed: 2454994. 5A1 binds both in vitro and in vivo PubMed: 10792003. The D24 antibody (ATCC CRL-2701) can be used with the 5A1 antibody (TS212820) in ELISA assays to quantitate the amount of naturally occurring mouse CSF-1 PubMed: 2677146. These antibodies recognize different epitopes of the same antigen, thereby permitting the detection of low amounts of CSF-1 PubMed: 2677146. The 5A1 antibody (TS212820) inhibits the clonal growth mouse granulocyte/macrophage colony forming cells (GM-CFC). |
| Genes Expressed: | immunoglobulin; monoclonal antibody; against colony stimulating factor-1 (CSF-1),colony stimulating factor 1 (macrophage) |
| Cellular Products: | immunoglobulin; monoclonal antibody; against colony stimulating factor-1 (CSF-1) |
| Tumorigenic: | Yes |
| Effects: | Yes, ascites in pristane primed Lou/M rats |
| Comments: | Animals were immunized with purified mouse colony stimulating factor-1 (CSF-1). Spleen cells were fused with Y3-Ag.1.2.3 myeloma cells. The D24 (ATCC CRL-2701) antibody binds to mouse CSF-1 but does not neutralize its biological activity while the 5A1 (TS212820) antibody binds to and neutralizes the biological function of CSF-1 PubMed: 2454994. 5A1 binds both in vitro and in vivo PubMed: 10792003. The D24 antibody (ATCC CRL-2701) can be used with the 5A1 antibody (TS212820) in ELISA assays to quantitate the amount of naturally occurring mouse CSF-1 PubMed: 2677146. These antibodies recognize different epitopes of the same antigen, thereby permitting the detection of low amounts of CSF-1 PubMed: 2677146. The 5A1 antibody (TS212820) inhibits the clonal growth mouse granulocyte/macrophage colony forming cells (GM-CFC). |
| Complete Growth Medium: | Alpha minimum essential medium with ribonucleosides and deoxyribonucleosides, 90%; fetal bovine serum, 10%
|
| Subculturing: | Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10(5) viable cells/ml. Interval: Maintain cell density between 2 X 10(5) and 1 X 10(6) viable cells/ml. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation: | Freeze medium: Complete growth medium supplemented with an additional 10% fetal bovine serum and 5% DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions: | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| Isotype: | IgG1 |
| Name of Depositor: | H Lin |
| Deposited As: | rat (B cell); rat (myeloma) |
| Year of Origin: | July, 1988 |
| References: | Lokeshwar BL, Lin HS. Development and characterization of monoclonal antibodies to murine macrophage colony-stimulating factor. J. Immunol. 141: 483-488, 1988. PubMed: 2454994 Lokeshwar BL, Lin HS. A sandwich enzyme-linked immunoadsorbent assay for detection of murine macrophage colony-stimulating factor (CSF-1). J. Immunol. Methods 123: 123-129, 1989. PubMed: 2677146 Cenci S, et al. M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss. J. Clin. Invest. 105: 1279-1287, 2000. PubMed: 10792003 |